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Abstract 
The occurrence of a mandibular lesion as the first sign of multiple myeloma (MM) is uncommon. This report descri-
bes a case of MM diagnosed because of a mandibular lesion. A 62-year-old woman presented a destructive radiolu-
cent lesion in the right mandibular ramus. The lesion caused rupture of the anterior cortical bone and extended from 
the retromolar area to the coronoid process. An incisional biopsy was performed. Histopathological examination 
revealed numerous pleomorphic plasma cells, some with binucleated nuclei. The tumor cells showed kappa light-
chain restriction. Bone marrow biopsy showed findings of massive infiltration of neoplastic plasma cells, besides 
lesions in the vertebrae. The diagnosis of MM was established. The patient underwent autologous hematopoietic 
stem-cell transplantation. Currently, the patient is under regular follow up after 40 months of initial treatment. In 
conclusion, MM should be considered in the differential diagnosis of destructive mandibular lesions.
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Introduction
Multiple myeloma (MM) is a relatively rare malignant 
neoplasm of plasma cells (1-6). The malignant cells are 
mainly characterized by the overproduction of a mono-
clonal kappa or lambda light chain antibody, with or wi-
thout an associated heavy chain. These immunoglobu-
lins may be found in serum or urine, and are known as M 
proteins in reference to multiple myeloma (4,5,7,8).
MM usually manifests as a tumor involving the marrow 
of several bones, and develops more commonly in the 
skull, vertebrae, and pelvis (2,9). The etiology is unk-
nown, although there is an increased risk in patients 
exposed to ionizing radiation. In many cases, it is as-
sociated with gene rearrangements due to chromosomal 
translocations in the immunoglobulin heavy chain re-
gion (3).
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The clinical features are related to the effects of prolifera-
tion and expansion of neoplastic plasma cells in the bone 
marrow, the excessive production of immunoglobulins, 
which often have abnormal physicochemical properties, 
and the suppression of normal humoral immunity. The 
primary manifestation is related to bone destruction in-
duced by tumor cells (4,10). Additionally, as consequen-
ce of abnormal accumulation of light chains of immuno-
globulins, approximately 15% of the patients with MM 
present amyloidosis. The amyloidosis may be the first 
sign of MM. The oral mucosa, particularly the tongue, 
is commonly affected by amyloidosis, which cause fre-
quently macroglossia (3).  
Histopathological analysis of bone biopsies in patients 
with MM have shown that increased osteoclastic acti-
vity occurs simultaneously with the development of the 
disease. This led to the hypothesis that local cytokines 
produced or induced by myeloma cells would be res-
ponsible for increased bone resorption activity. Simul-
taneously, because of the resorption process, the release 
of growth factors would increase the development of 
neoplastic plasma cells (11,12). Along with symptoms 
related to bone destruction, the patient has an increased 
risk of infections and fever, fatigue, anemia, nephropa-
thy, and temporal arteritis (2,3,10,13,14).
This disease accounts for approximately 1% of all 
malignancies and 10% of hematologic malignancies 
(2,6,9,10,13,15). It mainly affects men. It is primarily a 
disease of the elderly, affecting individuals aged 60 to 70 
years (2,6,10,13). The involvement of the maxilla and/or 
mandible is common, occurring in 30% of cases. Howe-
ver, the presence of maxillary or mandibular lesions as 
the first manifestation of the disease is rare (2,4,9,16). 
Thus, this report describes a case of multiple myeloma 
initially diagnosed because of a mandibular lesion.
Case Report
A 62-year-old woman sought treatment for a mandibular 
lesion present for about 2 months. The patient complai-
ned of swelling at the mandible, trismus, and paresthesia 
on the right side of the lip and tongue. The intraoral exa-
mination showed mild edema in the retromolar region, 
where palpation revealed bony crepitus.
A panoramic radiograph showed a multilocular radio-
lucent destructive lesion in the right mandibular ramus 
(Fig. 1). The lesion caused rupture of the anterior cortical 
bone, and extended from the retromolar area to the coro-
noid process. Ameloblastoma and odontogenic myxoma 
were the main hypotheses of diagnosis. In addition, a 
malignant neoplasm could not be ruled out. An incisio-
nal biopsy was performed under local anesthesia. Histo-
pathological examination revealed numerous pleomor-
phic neoplastic cells with eccentric nuclei and a large 
eosinophilic cytoplasm (Fig. 2). Immunohistochemistry 
showed neoplastic cells with plasmacytic differentia-
tion and monoclonality for kappa immunoglobulin light 
chains (Fig. 3), suggesting a diagnosis of plasmacytoma/
MM.
The patient underwent other clinical, imaging, and labo-
ratory tests to confirm the diagnosis. Bence Jones protein 
was positive in the urine. Protein electrophoresis perfor-
med with immunofixation with monospecific antisera 
for light and heavy immunoglobulin chains revealed the 
presence of a monoclonal IgG/kappa component. Bone 
marrow biopsy showed findings of massive infiltration 
of neoplastic plasma cells. In addition, the patient had 
diffuse lytic lesions in vertebral bodies causing corti-
cal thinning and slight protrusion of soft tissue into the 
medullary cavity. Similar lesions were observed in the 
sacrum. Accordingly, the diagnosis of MM was confir-
med. In oral cavity, macroglossia or any other signs of 
amyloidosis were not found.
The patient underwent chemotherapy with cyclophospha-
mide (50 mg), dexamethasone (40 mg), and thalidomide 
(100 mg). Intravenous zoledronate was administered, 
and 12 radiotherapy sessions (total dose: 24 Gy) were 
performed to control pain from the vertebral lesions. 
After chemotherapy, the patient underwent autologous 
Fig. 2. Several pleomorphic neoplastic cells with eccentric nuclei 
and a large eosinophilic cytoplasm (hematoxylin-eosin, x200). 
Fig. 1. Panoramic radiograph revealing a multilocular radiolucent 
destructive lesion in the right mandibular ramus.
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Fig. 3. Immunohistochemistry evidenced kappa immunoglobulin light chain (A) restriction 
(x400).
hematopoietic stem cell transplantation (ASCT). Today, 
40 months after diagnosis and initial treatment, the pa-
tient is under regular monitoring. Panoramic radiograph 
showed significant regression of mandibular lesion at 36 
months. The patient reported persistent paresthesia only 
on the right side of the tongue.
Discussion
MM is a characteristic disease of the elderly, with a 
slight tendency to affect men, and it is rarely diagnosed 
before 40 years of age. This disease is commonly dis-
seminated, involving multiple skeletal sites, and affects 
mainly the skull, pelvis, vertebrae, ribs, and long bones 
(9,17). In this case, besides the lesion in the mandible, 
lesions were observed in the vertebrae. When the man-
dible is involved, as occurs in about 30% of cases, MM 
especially affects the molar region, ramus, and angle, 
probably because these areas exhibit strong hematopoie-
tic activity (2,3,7,14).
Presentation in the mandible is particularly rare, and the-
re are few reports in the literature of mandibular lesions 
as the initial presentation of MM. Oral manifestations 
may include gingival bleeding, dental pain, paresthe-
sia, dental mobility, ulceration, and increased fullness 
(3,7,13,14,17,18). In this case, the clinical signs of ma-
lignancy included swelling at the site, trismus, and pa-
resthesia.
On radiography, the appearance of MM varies. It can 
present as multiple well-defined, or irregular and diffu-
se, radiolucent lesions (2-5,17). The radiographic pat-
tern in this case showed a destructive radiolucent lesion 
in the mandibular ramus associated with rupture of the 
anterior cortical bone. The differential diagnosis of mul-
tiple lesions with radiological findings of bony destruc-
tion includes metastatic disease, chronic osteomyelitis, 
and arteriovenous malformations (2,3). The differential 
diagnosis may also include benign odontogenic tumors, 
such as ameloblastoma, keratocystic odontogenic tumor, 
and odontogenic myxoma. Although rare in this age 
group, aggressive central giant cells lesions should also 
be included in the differential diagnosis (2).
The histopathological examination of MM shows diffuse 
and monotonous layers of neoplastic plasmacytoid cells, 
with variable degrees of differentiation that invade and 
replace normal host tissue. Mitotic activity can be seen 
with some frequency. Plasma cells of relatively normal 
appearance, plasmablasts with vesicular nuclear chroma-
tin and a single visible nucleolus, or bizarre multinuclear 
cells may predominate (8,13). Immunohistochemistry 
for kappa and lambda chains is commonly performed in 
order to characterize the monoclonal plasma cells that 
are observed in this disease (12). In this case, the histo-
pathological examination revealed numerous pleomor-
phic plasma cells, some of them bi-nucleate. Immuno-
histochemistry confirmed the diagnosis, with evidence 
of kappa light chain restriction.
The diagnosis of MM is based on clinical, imaging, 
histopathological, and laboratory findings (6). These in-
clude 10% or more monoclonal neoplastic plasma cells 
present on bone marrow examination, or the presence of 
a biopsy-proven plasmacytoma causing systemic patho-
logy, such as anemia, hypercalcemia, multiple osteolytic 
lesions, and renal failure (6,10,13,15). Furthermore, the 
presence of more than 60% monoclonal plasma cells in 
the bone marrow points to the diagnosis of myeloma, wi-
thout the existence of lesions in other organs (10). In this 
case, after the incisional biopsy and confirmation of the 
monoclonal neoplastic nature by immunohistochemistry, 
other lesions were found in the vertebrae, in addition to 
massive neoplastic marrow infiltration by plasma cells, 
and the presence of a monoclonal IgG/kappa component 
on protein electrophoresis.
The treatment of MM varies considerably among institu-
tions and countries. This variation stems from the avai-
lability and cost of new drugs, and is related to different 
philosophies and interpretations of scientific data (6,15). 
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In general, initial therapy is based on the consideration 
of ASCT. These patients should be less than 65 years 
of age, without other systemic limitations (6,9,15), as 
in this case.
The first attempt to control the disease generally consists 
of chemotherapy. An alkylating agent, such as melpha-
lan, is often administered with prednisone or dexametha-
sone (3,9). For patients selected for ASCT, an induction 
regimen is devised that does not contain melphalan with 
prednisone as a single agent, or a combination with ano-
ther agent, such as lenalidomide, is administered; ASCT 
follows, as an early or late approach after the first relap-
se (3,6,10,15). Chemotherapy with a combination of cy-
clophosphamide, thalidomide, and dexamethasone (19), 
as used in this case, has been shown to be an effective 
induction regimen prior to ASCT in patients with MM. 
Other regimens using thalidomide, bortezomib, and le-
nalidomide are being used for some induction therapy, 
maintenance therapy, and relapse phases of the disea-
se, and may be responsible for the significant increase 
in the survival time of patients seen in the last decade 
(3,9,10,15).
For patients who have no indication for ASCT, 12-18 
months of treatment with melphalan or a regimen used 
in ASCT patients may also be applied in this group. 
Inevitably, most patients will relapse, with progressive 
decreases in the duration of disease remission with each 
rescue therapy (10,15).
Bisphosphonates are used as complementary treatment, 
by inhibiting bone resorption and reducing pathologic 
fractures and hypercalcemia (3,5), as in this patient. The 
duration of therapy is indefinite, but some authors advo-
cate a limitation, due to the risk of osteonecrosis of the 
jaw following invasive dental procedures, particularly 
dentoalveolar surgery. To avoid such adverse effects, the 
involvement of the dental surgeon is essential. Patients 
should be periodically monitored to maintain excellent 
oral health (3,14,16). In addition, radiotherapy may be 
used in combination with other therapies in cases with 
painful bone lesions. Approximately 30% of patients 
will need this therapy (3,11), as in this case.
The prognosis is usually unfavorable, but is variable and 
depends on many factors, such as the patient’s age, sta-
ge of disease, related genetic changes, and response to 
therapy (3,10). Patients undergoing ASCT can survive 
for more than 10 years, which shows that it can prolong 
life, but is not curative. The mean survival is 5 years, 
and cure has not yet been achieved (3,6). Our patient un-
derwent ASCT, and the disease remains under control.
In conclusion, MM is an aggressive, relatively rare 
malignant neoplasm that usually affects the marrow at 
several skeletal sites. The mandible will be affected in 
about 30% of cases, but the initial presentation with da-
mage to gnathic bones is particularly rare. Owing to ra-
diographic appearance similar to other diseases, clinical 
and laboratory evaluation, including histopathological 
examination, should be done to confirm the diagnosis. 
In addition, the dental practitioner must be aware that 
MM should be considered in the differential diagnosis 
of mandibular destructive lesions, particularly in elderly 
patients.
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